On June 26, 2025, Revolution Medicines, Inc. held its annual stockholder meeting where stockholders elected four directors, ratified the accounting firm PricewaterhouseCoopers LLP, and approved an advisory executive compensation proposal. They reported 186,261,742 shares eligible for voting on that date.